SVRA
Savara Inc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsSavara Inc
Expected move
InputsSavara Inc
4.76
+0.02 · +0.53%
post 4.82 +1.37%
Bull1
Bear2
No other changes.
No other changes.
| Manager | Value | % base | |
|---|---|---|---|
| NEA | $150.7M | 11.26% | 0.00% |
| Bain Capital Life Sciences Investors | $108.4M | 8.10% | 0.00% |
| VR Adviser | $90.8M | 6.78% | +7.32% |
| Deerfield | $83.6M | 6.24% | 0.00% |
| BlackRockindex-like | $77.0M | 5.75% | +10.66% |
| Manager | Value | % base | |
|---|---|---|---|
| NEA | $150.7M | 11.26% | 0.00% |
| Bain Capital Life Sciences Investors | $108.4M | 8.10% | 0.00% |
| VR Adviser | $90.8M | 6.78% | +7.32% |
| Deerfield | $83.6M | 6.24% | 0.00% |
| BlackRockindex-like | $77.0M | 5.75% | +10.66% |
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Savara Inc's 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Savara Inc's 6 closest co-movers, none share that code.
Annual filing, covered
10-K parsed · Mar 13 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 13 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Tall tick = annual report · Source: EDGAR
No thesis.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
—
—
Expected move
No implied move.